Healthineers Draws Split Verdicts as Buyback, Renaming and Diagnostics Split Reshape the Story
Published on 11/16/2026 at 02:01 | Editorial boerse-global.deSiemens Healthineers spent the second week of November ticking several boxes at once: a fresh batch of treasury shares, a proposed dividend, a rebrand, and the first concrete step toward spinning off its diagnostics arm. Analysts, meanwhile, were busy moving in opposite directions.
The medical-technology group confirmed on 9 November that it bought back 50,000 of its own shares between 2 and 8 November. Since the programme began on 1 June, roughly 3.68 million shares had been repurchased through 8 November.
Alongside its annual results on 5 November, the company proposed a dividend of €1.00 per share. Adjusted unadjusted earnings per share came in at €2.42, on revenue of €23.63 billion and an adjusted EBIT margin of 16.2%. Comparable revenue growth for the year reached 4%, accelerating to 5.9% in the fourth quarter.
A 2027 guide that fell short
For 2026/27, Healthineers guided to comparable revenue growth of 4–5% and adjusted earnings per share of €2.20–2.40. By the company's own account, that outlook landed below market expectations: analysts polled by dpa-AFX had pencilled in 5.5% comparable growth and €2.37 per share.
Should investors sell immediately? Or is it worth buying Siemens Healthineers?
The fourth-quarter figures also included an adjusted EBIT margin of 15.9% and free cash flow of €703 million.
Diagnostics to stand alone as Olyrian
On 6 November, the group set the carve-out of its in-vitro diagnostics business in motion, preparing the unit to operate as a standalone company called Olyrian Diagnostics. The transition is expected to be completed by mid-2028.
That same day, Healthineers announced it intends to rename itself simply "Healthineers." Shareholder approval at the annual general meeting in February 2027 is required. The brand change is slated to begin after the spin-off planned for 2027 and to roll out over three years.
Siemens Healthineers at a turning point? This analysis reveals what investors need to know now.
Targets up, one rating down
Goldman Sachs raised its price target to €49 from €43 on 9 November, keeping a "Neutral" stance. Jefferies moved in the same direction the same day, lifting its target to €55 from €50 while reaffirming "Buy."
Not everyone turned more constructive. Bernstein Research downgraded the stock from "Outperform" to "Market-Perform" on Friday, trimming its target to €44 from €44.50. The shares added 1.1% on Friday to close at €44.01.
Ad
Siemens Healthineers Stock: New Analysis - 16 November
Fresh Siemens Healthineers information released. What's the impact for investors? Our latest independent report examines recent figures and market trends.
